Navigation Links
Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer
Date:7/23/2014

(Philadelphia, PA) Asking patients if a suspicious skin lesion is painful or itchy may help doctors decide whether the spot is likely to be cancerous, according to a new study headed by Gil Yosipovitch, MD, Chairman of the Department of Dermatology at Temple University School of Medicine.

The study, published online by JAMA Dermatology on July 23, 2014, found that nearly 36. 9 percent of skin cancer lesions are accompanied by itching, while 28.2 percent involve pain. Non-melanoma skin cancers specifically, basal cell carcinoma and squamous cell carcinoma are more likely than melanoma to involve itch or pain, the study found.

"The study highlights the importance of a simple bedside evaluation for the presence and intensity of pain or itch as an easily implementable tool for clinicians in evaluating suspicious skin lesions," concluded the study.

Dr. Yosipovitch, Director of the Temple Itch Center, said the findings are important because skin cancer is the most common cancer in the United States. More than 3.5 million non-melanoma skin cancers are diagnosed in two million people annually in this country.

"Patients sometimes have multiple lesions that are suspicious looking, and those that are itchy or painful should raise high concerns for non-melanoma skin cancers," Dr. Yosipovitch said.

The study involved 268 patients who had 339 laboratory-confirmed skin cancer lesions at Wake Forest University Baptist Medical Center from July 2010 to March 2011.

After undergoing a skin biopsy, the patients were asked to complete a numerical ranking scale to quantify the intensity of itch and pain associated with their skin lesion. The scale, called a visual analog scale, or VAS, went from zero (no sensation) to 10 (the most intense sensation imaginable).

When the researchers compared the patients' responses to their biopsy results, they found that:

  • The prevalence of itch was greatest in squamous cell carcinoma (46.6 percent), followed by basal cell carcinoma (31.9 percent) and melanoma (14.8 percent).
  • Pain prevalence was greatest in squamous cell carcinoma (42.5 percent), followed by basal cell carcinoma (19.9 percent) and melanoma (3.7 percent).
  • Pain and itch often went hand in hand: 45.6 percent of lesions associated with itch also had pain; and 60 percent of painful lesions also involved itch.
  • The most painful lesions tended to be those with the greatest depth (except for melanoma lesions, which did not correlate with pain). Pain and itch was also associated with lesions that were larger in diameter. Cancers that were ulcerated (sores or open wounds) tended to be associated with pain but not with itch.
  • Pain and/or itch were more likely to be present when the laboratory analysis of the skin lesion sample suggested a marked or moderate degree of inflammation as compared to mild or no inflammation.

Dr. Yosipovitch said he hopes the study findings will prompt dermatologists to incorporate the use of a ranking scale for pain and itch when evaluating patients with suspicious skin lesions.

This could increase the detection of skin lesions that are cancerous," he said.


'/>"/>

Contact: Jeremy Walter
Jeremy.Walter@tuhs.temple.edu
267-838-0398
Temple University Health System
Source:Eurekalert

Related medicine news :

1. Global food safety research agreement signed by China and UC Davis
2. Researchers unlock the protein puzzle
3. Historical and Current Research Points to Importance of Breast Self-Exams
4. China Hemodialysis Equipment Market (Import & Export) Report 2013-2016 Now Available at ChinaMarketResearchReports.com
5. New Research Finds Pretreatment of Mesothelioma Cells with These Two Compounds Boosts Chemotherapy Response, According to Surviving Mesothelioma
6. University of Utah researcher Robert Marc receives Paul Kayser International Award
7. New research finds pathogenic connection between autoimmune disorders and cancer
8. Research brings us nearer to understanding how neuro cells turn cancerous
9. Global Molecular Diagnostics Market Expected to Reach USD 8.7 Billion through 2019: Transparency Market Research
10. SkillSurvey to Present Research on Contingent Workers at National Association for Health Care Recruitment IMAGE 2014 Conference
11. Growth of Disposable Medical Supplies Market to 2019 Report Available at RnRMarketResearch.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... ... ... to Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. ... , What are the critical reimbursement questions manufacturers should be asking ...
(Date:2/17/2017)... Seattle, WA (PRWEB) , ... February 17, 2017 ... ... health management organizations, has been named a finalist in the 8th Annual DecisionHealth ... impacting America's healthcare delivery system. Qualis Health’s work is recognized across multiple award ...
(Date:2/17/2017)... Tx (PRWEB) , ... February 17, 2017 , ... ... revenue cycle management services, announced today that Karen Pilley has been promoted to ... is critical in today’s shifting healthcare paradigm – a shift that demands the ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer ... Molecular Medicine Tri-Conference February 20 – 22 in San Francisco. As part of ... anatomic and molecular pathology workflow solution, as well as its new precision medicine ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Mason Pasquin Agency, ... and business owners in and around the Hampton Roads metropolitan region, is joining ... forms of domestic violence. , There are multiple categories of domestic violence – ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Feb. 17, 2017  BioDigital, Inc., creators of ... of their 3D body mapping technology with eClinicalWorks, ... new integration will be used to capture and ... of the human body. BioDigital pilots show using ... while also increasing the precision of clinical annotations ...
(Date:2/16/2017)... Feb. 16, 2017 Research and Markets ... Emerging Medical Device Technologies" report to their offering. ... Traditional ... procedures, general instruments, non-drug coated implantables, large endoscopes, needle based ... use over the last two to three decades for the ...
(Date:2/16/2017)... MISSISSAUGA, Ontario , Feb. 16, 2017  Aralez ... a global specialty pharmaceutical company, today announced that executive ... Healthcare Conference to be held February 22-23, 2017. ... overview of the Company at 1:35 p.m. local time ... webcast and audio archive for the event may be ...
Breaking Medicine Technology: